Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 3/20 | 0.69 |
| ▸ | BRAF | P15056 | 10/20 | 0.49 |
| ▸ | MAP4K1 | Q92918 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CLK1 | P49759 | 1/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | JUN | P05412 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13252801 | 0.88 | MAP3K5 (0.69) | MAP3K5BRAFMAP4K1ROCK2JUN | |
| SCHEMBL3504879 | 0.86 | MAP3K5 (0.66) | MAP3K5BRAFMAP4K1ROCK2JUN | |
| SCHEMBL1866197 | 0.85 | MAP3K5 (0.51) | MAP3K5BRAFMAP4K1MEN1CYP1A2 | |
| SCHEMBL14146425 | 0.84 | MAP3K5 (0.51) | MAP3K5BRAFMAP4K1JUNMAPK10 | |
| SCHEMBL1571282 | 0.83 | BRAF (0.55) | MAP3K5BRAFMEN1CYP1A2CYP3A4 | |
| SCHEMBL1867274 | 0.82 | MAP3K5 (0.55) | MAP3K5BRAFMEN1CYP1A2CYP3A4 | |
| SCHEMBL1872204 | 0.82 | MAP3K5 (0.60) | MAP3K5BRAFMAP4K1ROCK2 | |
| SCHEMBL1570946 | 0.80 | BRAF (0.49) | MAP3K5BRAFMAP4K1MEN1CYP1A2 | |
| SCHEMBL1570944 | 0.79 | MAP3K5 (0.47) | MAP3K5BRAFMAP4K1MEN1CYP1A2 | |
| SCHEMBL1866931 | 0.78 | MAP3K5 (0.50) | MAP3K5BRAFMEN1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008079988-A9 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2011-05-12 | — | — | WO | claimed |
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | AIKAWA MINA | 2010-08-26 | — | — | US | claimed |
| WO-2008079988-A9 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2011-05-12 | — | — | WO | disclosed |
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | AIKAWA MINA | 2010-08-26 | — | — | US | disclosed |
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | AIKAWA MINA | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | MAP3K5 24/4885BRAF 316/4885MAP4K1 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.